Pharmaceuticals

New guidelines for ankle arthritis, a condition hitting younger workers hard, expose major gaps in medical research and a market ripe for innovation.

At Boston's Wedbush Renal Summit, Hansa Biopharma showcases its game-changing transplant drug, signaling a major strategic play for the lucrative U.S. market.

A massive financing round for deupirfenidone isn't just about a potential new IPF drug; it's a masterclass in biotech strategy, validating a model that promises value for all.

Michael Goettler leaves the Bausch Health board to lead Knoa Pharma, a firm born from Purdue's ashes. A look at the strategic move shaking up pharma.

A new study for CRENESSITY could revolutionize care for infants with classic congenital adrenal hyperplasia, shifting the treatment paradigm and solidifying market leadership.

Advicenne's unlimited UK drug approval for Sibnayal® is a win for rare disease patients, but it's one piece in a high-stakes global strategy now targeting the US market.

Rentschler Biopharma appoints Dr. Torsten Woehr as CEO, a strategic move to deepen its core biologics focus after exiting cell and gene therapy.

As lawsuits allege a link between blockbuster weight-loss drugs like Ozempic and irreversible blindness, a critical question emerges: Who guards our health?

A surge in biotech innovation is set to transform the high-grade glioma market. With a pipeline of targeted drugs and vaccines, a once-stagnant field is now a beacon of hope.

Oryzon Genomics secures a dual funding package, navigating market jitters to accelerate its pioneering cancer and psychiatric drug pipelines with EU backing.

Artelo's latest data on its non-opioid pain drug ART26.12 could unlock a massive market, but what are the real risks and rewards for this clinical-stage biotech?

Vyome Holdings secures a key patent in China, not by betting the farm, but by making a shrewd, capital-efficient move to tap into a massive future market.

As Merck preps for its August 4th earnings call, investors look past Q2 numbers to see if a flurry of deals and pipeline wins can build a new empire.

As Sobi prepares its Q2 2026 report, all eyes are on its booming immunology unit. After a stellar Q1, the key test is sustaining that momentum.

Millions of older Americans can now access the popular weight-loss drug Wegovy for a $50 copay, a temporary move that could reshape healthcare policy and the pharma market.

Galderma's innovative neuromodulator, a key to its 'powerhouse' ambitions, hits a U.S. roadblock. The FDA's concerns? Manufacturing, not safety.

The FDA's approval of a potent new triglyceride drug comes with a staggering price tag, forcing a showdown with an established, affordable therapy.

Tiny, unlisted impurities in research chemicals can derail studies and undermine scientific integrity. A new analysis reveals the rigorous standards we should demand.

Once a quiet niche, the wAIHA market is now a battleground for J&J, Sanofi, and Novartis, with a 14.4% growth forecast and a new class of drugs.